The growth in the pipeline of nephrotic syndrome is attributed to the increase in prevalence of individuals affected with diabetes, hypertension and hyperlipidaemia. Unhealthy lifestyle and unhygienic crops and fruits are also the factors that are contributing to the growth of therapeutic pipeline of nephrotic syndrome. Environmental factors are also thought to be responsible for occurrence of nephrotic syndrome. Funds from various organizations are contributing to the research and developments in the therapy area which in turn is believed to help in early diagnosis of the disease.
Nephrotic syndrome is a collection of symptoms such as, proteinuria, hyperlipidemia, edema or swelling and hypoalbuminia, which mainly affects kidneys. Edema is caused when albumin leaks into the urine and body loses its capacity to absorb its extra fluid. The anomalies in kidney filters, glomeruli, is the main risk factor of nephrotic syndrome. Tiny blood vessels in glomeruli removes waste and excess fluid from blood and direct them to urinary bladder in the form of urine. Nephrotic syndrome can also be caused by metabolic disease such as diabetes and lupus. Weight gain, fatigue, foamy urine and loss of appetite are the main symptoms observed in patients with nephrotic syndrome. Complication associated with nephrotic syndrome are hypothyroidism, anemia, coronary artery disease or coronary heart disease, high blood pressure or hypertension and acute kidney injury.
Many companies have conducted clinical trials for evaluating the effectiveness and safety of the drugs for the treatment of nephrotic syndrome. The drugs have shown promising results in the treatment of the disease. For example, Rituximab from F. Hoffmann-La Roche AG in Phase II/III, Mizoribine from Asahi Kasei Pharma Corporation in Phase III, ACTH from Mallinckrodt LLC in Phase III, Mycophenolic acid from Novartis AG in Phase III, Abatacept from Bristol-Myers Squibb Company in Phase II, NC-503 from Bellus Health Inc, Ltd. in Phase II/III, etc. Acthar gel is thought to be a treatment option for Nephrotic syndrome. According to the Journal BMC Nephrology, a clinical study was conducted in May 2016, by a group of Nephrology Associates of Central Florida in Orlando in 37 patients with nephrotic syndrome, out of which 62.2% patients experienced significant reduction in proteinuria.
In 2014, Anthera Pharmaceuticals, Inc. and Zenyaku Kogyo Co., Ltd. of Japan entered a license agreement, under the terms of which Zenyaku Kogyo Co., Ltd. got the rights for the development and commercialization of subcutaneous blisibimod in Japan and potentially in other Asian countries. In October 2014, the National Institutes of Health announced to provide funding of $5.8 million over a five-year period to the Nephrotic Syndrome Study Network, also known as NEPTUNE.
Some of the companies having a pipeline of nephrotic syndrome therapeutics include, F. Hoffmann-La Roche AG, Asahi Kasei Pharma Corporation, Mallinckrodt LLC, Novartis AG, Bristol-Myers Squibb Company, Genentech, Inc., Bellus Health Inc., GlaxoSmithKline plc, Retrophin, Inc., Concert Pharmaceuticals Inc.